AbCellera Biologics Stock
AbCellera Biologics Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- CEO
- Carl Hansen
- Employees
- 562
- Market cap
- $3.8 B
- IPO
- 11/12/2020
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had…
AbCellera Biologics stock: price history
1D
-6.9%
1W
-6.0%
1M
+1.1%
6M
+194.3%
YTD
+245.0%
1Y
+102.1%
2Y
+350.4%
5Y
-24.0%
10Y
–
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~57% stronger price swings than usual
AbCellera Biologics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 16/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
2 more assignments (Enabler/Second row) Pro-only.
AbCellera Biologics Inc. uses an AI-powered platform to identify antibodies through the analysis of natural immune systems. The company supports the pharmaceutical industry in the discovery of novel therapeutics by providing highly specialized research services and technological infrastructure. Revenue streams are primarily based on licensing fees and research fees, supplemented by milestone payments. Through collaborations with various partners, such as Eli Lilly and Company, the company manages a diverse portfolio of research programs at different stages of development.
- Revenue model
- Mixed
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Suppliers & customers in our universe
Eli Lilly and CompanyDescription
Eli Lilly and CompanyDescriptionAsk the agents about AbCellera Biologics
Analyst assessment of AbCellera Biologics
PRICE TARGET LOW
US$7.00
CONSENSUS
US$15.40
MEDIAN
US$13.00
PRICE TARGET HIGH
US$30.00
0
STRONG BUY
11
BUY
1
HOLD
0
SELL
0
STRONG SELL
12
TOTAL · Buy
As of: 11/08/2026
AbCellera Biologics stock metrics
P/E
-21.85
P/B
4.02
EV/EBITDA
-22.72
RETURN ON EQUITY
-6.2%
NET MARGIN
-1,368.6%
DEBT/EQUITY
0.15
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
64.5%
FLOAT SHARES
209,038,499
AVG. DAILY VOLUME (30D)
5,026,011
Insider transactions (SEC)
Hayden Michael R
Montalbano John S.
Hayden Michael R
Booth Andrew
Hayden Michael R
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -6.9%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about AbCellera Biologics stock
What does AbCellera Biologics do?
AbCellera Biologics Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in Canada.
The CEO is Carl Hansen, the company employs around 562 people.
The IPO was on 11/12/2020; the stock trades on NASDAQ under the ticker ABCL.
What do analysts say about AbCellera Biologics stock?
12 analysts rate the stock, the consensus is Buy (as of 11/08/2026).
The average price target is US$15.40, ranging from US$7.00 to US$30.00, with a median of US$13.00.
This is an external assessment, not a statement by Market Jury.
When does AbCellera Biologics report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 57% stronger than usual.
Does AbCellera Biologics pay a dividend?
No, AbCellera Biologics currently does not pay a dividend.
Which stocks are comparable to AbCellera Biologics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get AbCellera Biologics stock analyzed?
Clicking "Analyze stock" lets five strategies assess AbCellera Biologics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.